Topics covered include: the global market in a historical context; and the outlook of "macro misery", having regard to unemployment, inflation, and the likelihood of recession and tighter monetary policy.
Copyright 2022 – Finance News Network
Source: Finance News Network
23 Nov 2022 - Altech Chemicals Limited (ASX:ATC) CFO Martin Stein discusses the recent joint venture with Fraunhofer IKTS and the CERENERGY solid state sodium alumina battery.
Read More21 Jul 2021 - icetana (ASX:ICE) CEO and Managing Director Matt Macfarlane provides an update for the June quarter 2021.
Read More03 Aug 2020 - Kingston Resources Limited (ASX:KSN) Managing Director Andrew Corbett provides an update on the company's Misima and Livingstone Gold Projects.
Read More16 June 2020 - Social Tree Global co-founders, Max Hannah and James Saward-Anderson share their top 5 hacks for harnessing the power of social media in financial services.
Read More05 Jun 2023 - Magontec Limited (ASX:MGL) Executive Chairman Nicholas Andrews, Chinese President Tong Xunyou and Non-Executive Director Li Xingcai discuss record financial results, and technical milestones in the extraction of magnesium from salt lakes.
Read More10 Mar 2020 - Opthea Limited (ASX:OPT) Managing Director and CEO, Dr Megan Baldwin talks about results from the company's lead drug candidate OPT-302, and new funding for further clinical development for wet AMD (age-related macular degeneration) and DME (diabetic macular degeneration).
Read More01 Sep 2021 - Novatti Group Limited (ASX:NOV) CEO Peter Cook, discusses highlights from FY21, including growth in partners and transactions as the company's technology finds greater adoption and new markets.
Read More06 Apr 2020 - Cyclopharm (ASX:CYC) CEO & Managing Director, James McBrayer talks about its new drug application with the US FDA for Technegas and applications beyond pulmonary embolism in chronic chronic obstructive pulmonary ( COPD ) and asthma.
Read More28 Sep 2020 - Respiri Limited (ASX:RSH) CEO Marjan Mikel discusses clinical results from the company's innovative asthma management tool wheezo, a combination eHealth app and handheld device, as well as the company's strategy and outlook.
Read More27 Apr 2020 - Kazia Therapeutics (ASX:KZA) CEO & MD, Dr. James Garner talks about its Phase II interim results for its glioblastoma drug candidate paxasilib, its pivotal GBM AGILE Phase II clinical study to commence 2H20 and value drivers as the company moves toward registration.
Read More
